Last reviewed · How we verify
Bisoprolol+pyridostgmine
Bisoprolol blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission.
Bisoprolol blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission. Used for Myasthenia gravis with concurrent hypertension or arrhythmia (investigational combination).
At a glance
| Generic name | Bisoprolol+pyridostgmine |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Beta-1 selective adrenergic antagonist + Cholinesterase inhibitor combination |
| Target | Beta-1 adrenergic receptor; Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Neuromuscular |
| Phase | FDA-approved |
Mechanism of action
Bisoprolol is a selective beta-1 blocker that decreases cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Pyridostigmine is a cholinesterase inhibitor that prolongs acetylcholine action at the neuromuscular junction, improving muscle strength. This combination is used to address both cardiovascular and neuromuscular symptoms, particularly in conditions where both beta-blockade and cholinergic enhancement are therapeutically beneficial.
Approved indications
- Myasthenia gravis with concurrent hypertension or arrhythmia (investigational combination)
Common side effects
- Bradycardia
- Fatigue
- Dizziness
- Muscle cramps
- Increased salivation
Key clinical trials
- Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisoprolol+pyridostgmine CI brief — competitive landscape report
- Bisoprolol+pyridostgmine updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI